In what ways has Bristol Myers Squibb helped move the needle towards improved patient care for those living with blood cancer?
Every day we leverage the latest science and technology to develop therapies that push beyond what is currently available to patients living with rare blood cancers and disorders.
Through our strong heritage and robust portfolio of treatment options in multiple myeloma, we have shaped the treatment paradigm as demonstrated through our long experience with IMiD® agents and subsequent research into new CELMoD® agents. We are also working hard to address the burden of relapses for multiple myeloma and lymphoma patients by exploring alternate pathways including CAR T cell therapy that may contribute to patients living longer.
There has been tremendous progress in leukemia in which our multiple therapies for acute (fast-growing) myeloid leukemia have helped to broaden the treatment landscape including targeted therapies directed against mutations. We have also established our therapeutic leadership across the myeloid space, with new treatment options for both myelodysplastic syndromes (MDS) and myelofibrosis (MF) – diseases that previously had been without innovation for more than a decade.
We understand that with each advancement comes a new opportunity to potentially help patients achieve complete remission, decrease the likelihood of relapse and extend overall survival. Through our broad clinical development program and diverse portfolio, we are evaluating a range of potential new therapies and combinations for blood cancers that remain hard-to-treat, in an effort to leave no patient behind.